2.175  -0.035 (-1.58%)		01-21 10:27
Open: 2.18 High: 2.1938 Volume: 38,227		Pre. Close: 2.21 Low: 2.15 Market Cap: 1(M)

Short term
Mid term
Targets	6-month :	6.13	1-year :	8.43
Resists	First :	5.24	Second :	7.21
Pivot price	2.31
Supports	First :	2.05	Second :	1.71
MAs	MA(5) :	2.2	MA(20) :	2.51
	MA(100) :	5.37	MA(250) :	12.88
MACD	MACD :	-0.7	Signal :	-0.7
%K %D	K(14,3) :	19	D(3) :	11.9
RSI	RSI(14): 39.1
52-week	High :	92	Low :	2.05

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ BDRX ] has closed above bottom band by 26.2%. Bollinger Bands are 85.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	2.29 - 2.31	2.31 - 2.32
Low:	2.17 - 2.18	2.18 - 2.2
Close:	2.19 - 2.21	2.21 - 2.23

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Tue, 06 Jan 2026
Biodexa Pharmaceuticals Names Fiona Sharp CFO and Board Director - TipRanks

Mon, 05 Jan 2026
Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary - GlobeNewswire

Mon, 05 Jan 2026
Biodexa Pharmaceuticals promotes Fiona Sharp to CFO and board director - MSN

Mon, 05 Jan 2026
Biodexa Pharmaceuticals PLC Appoints Fiona Sharp as Chief Financial Officer and Company Secretary - Quiver Quantitative

Mon, 05 Jan 2026
From health board to pharma board: Fiona Sharp takes top finance role - Stock Titan

Sun, 28 Dec 2025
Biodexa Pharmaceuticals Faces Market Challenges as Stocks Decline - StocksToTrade

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	1 (M)
Shares Float	61,440 (M)
Held by Insiders	0.9 (%)
Held by Institutions	4.4 (%)
Shares Short	43 (K)
Shares Short P.Month	124 (K)

EPS	-26.77
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	24.7
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-39.1 %
Return on Equity (ttm)	-61.8 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	-5.86
Sales Per Share	0
EBITDA (p.s.)	-10.58
Qtrly Earnings Growth	0 %
Operating Cash Flow	-11 (M)
Levered Free Cash Flow	-9 (M)

PE Ratio	-0.09
PEG Ratio	0
Price to Book value	0.08
Price to Sales	0
Price to Cash Flow	-0.18

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.